HR positive + HER-2 negative

P2, N=976, Recruiting, MedSIR | Trial completion date: Dec 2028 --> Jun 2028 | Trial primary completion date: Dec 2028 --> Jun 2028

Chidamide combined with fulvestrant showed encouraging antitumor activity and tolerable toxicity in pts with HR + /HER2- advanced breast cancer that had progressed after previous endocrine therapy. Trial registration ChiCTR2100044282, registered on March 14th 2021.

This report is the first highlighting the imaging characteristics of rapid-onset hepatic atrophy associated with abemaciclib-induced liver injury. These findings may provide useful insights for distinguishing abemaciclib-induced liver injury from other etiologies.

P=N/A, N=81, Not yet recruiting, University Hospital, Grenoble

Eribulin plus gemcitabine is effective and well-tolerated in patients with HER2-negative metastatic breast cancer needing second-line or later treatment, providing a valuable treatment option.

We retrospectively analyzed 156 women with HR+/HER2- MBC (hormone-receptor-positive, Her2-negative metastatic breast cancer) who initiated ribociclib or palbociclib plus endocrine therapy between May 2020 and January 2024. Routine body composition assessment may refine risk stratification and identify candidates for supportive interventions. Prospective studies are needed to validate these findings.

This case highlights the need to consider NF in post-chemotherapy patients presenting with erythema and systemic symptoms, even after a single dose, particularly when risk factors such as diabetes and obesity are present. Prompt recognition and intervention remain essential to improve survival.

A post-hoc power analysis based on these results showed a moderate power (0.59) to detect the observed difference.ConclusionsHER2-low expression may negatively influence chemosensitivity in hormone receptor-positive breast cancer treated with neoadjuvant chemotherapy. Further studies are warranted to evaluate the potential role of trastuzumab deruxtecan (T-DXd) and other antibody-drug conjugates in this newly defined subgroup.

Using HR+/HER2- BC models with acquired resistance to the CDK4/6 inhibitors Palbociclib or Ribociclib, we uncovered a metabolic vulnerability in highly resistant clones, mediated by mTORC1 hyperactivation and autophagy suppression. Gene expression profiling revealed enrichment of glycolysis and mTORC1 pathways in CDK4/6i-resistant cells, which manifested as heightened sensitivity to the metabolic inhibitors Metformin and Dichloroacetate (DCA)...Clinically, immunohistochemical analysis of a BC cohort revealed a significant correlation between mTORC1 activity (p4E-BP1T37/46) and autophagy suppression (p62 accumulation), supporting the translational relevance of this axis. Our findings propose mTORC1-mediated autophagy defects as a biomarker for metabolic vulnerability in CDK4/6i-resistant BC, offering a rationale for targeting these tumors with metabolic therapies to overcome resistance.

She received ribociclib with a reduced dose due to haematological toxicity, as well as letrozole and denosumab due to bone metastasis. Ribociclib was administered safely and effectively for nine months.DiscussionWe presented our experience of using ribociclib in a patient with metastatic breast cancer who was receiving hemodialysis. Ribociclib was administered safely, and a response to the treatment was achieved.

P1/2, N=1071, Recruiting, Medica Scientia Innovation Research S.L.

P1/2, N=36, Recruiting, Novartis Pharma AG